Aptose Biosciences, Inc. (APTO) PT Set at $4.00 by HC Wainwright
Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) has been assigned a $4.00 price target by equities researchers at HC Wainwright in a note issued to investors on Monday. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 196.30% from the company’s current price.
Several other equities research analysts have also issued reports on the stock. Roth Capital restated a “buy” rating and set a $5.00 price target on shares of Aptose Biosciences in a research note on Monday, October 23rd. ValuEngine lowered shares of Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research upgraded shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $5.90.
Shares of Aptose Biosciences (APTO) traded up 9.63% during midday trading on Monday, hitting $1.48. The stock had a trading volume of 469,736 shares. Aptose Biosciences has a 52 week low of $0.78 and a 52 week high of $1.79. The company’s market cap is $35.56 million. The stock’s 50-day moving average price is $1.48 and its 200 day moving average price is $1.31.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.07. On average, equities analysts forecast that Aptose Biosciences will post ($0.88) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Aptose Biosciences, Inc. (APTO) PT Set at $4.00 by HC Wainwright” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/30/aptose-biosciences-inc-apto-pt-set-at-4-00-by-hc-wainwright.html.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.